All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Astrid PavlovskyDuring the International Symposium on Hodgkin Lymphoma (ISHL) 2022 meeting, the Lymphoma Hub spoke with Astrid Pavlovsky, Fundaleu, Buenos Aires, AR. We asked, When and how should treatment be modified for older patients with HL?
When and how should treatment be modified for older patients with HL?
Pavlovsky begins by outlining why patients with HL >60 years of age typically have poor outcomes compared with younger patients. Pavlovsky then discusses the challenges faced when treating older patients with HL and reviews the latest clinical trial data for novel agents and combination therapies in this difficult-to-treat population.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average time to secure a reimbursed CAR T-cell therapy manufacturing slot for patients with DLBCL (from decision to treatment with a CAR T-cell therapy)?